Peterlin P, Jullien M. Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome/chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies. Haematologica 2025;110(5):1237; https://doi.org/10.3324/haematol.2025.287378.